Member Info for Elartu

Korean Society for Radiation Oncology

https://twitter.com/FBKmed/status/1049983603466231811

Not so late Horsford. Just up pondering on whether TexRAD might prove useful to these guys.

https://cancergenome.nih.gov/abouttcga/overview

https://twitter.com/FBKmed/status/1049656417559474176

Clearly stated by Feedback. It is for 'growth opportunities'.

"The Company is considering additional funding for its mid-term working capital requirements and to deliver on its longer-term growth opportunities and plans to raise the additional capital through public or private financings and/or partnering opportunities."

"Feedback is seeing considerable sales growth potential in the near to mid-term, especially in Asia. In order to enable it to also address the huge potential in the US market for the mid to long term, the Company has initiated plans for regulatory approval of TexRAD with the US FDA including 510k as medical device and CFR Chapter 21 part 11 compliance for use in clinical trials of drug candidates for FDA marketing approval."

I could be wrong here but have always been under the impression that 'near-term' funding was for use in the current financial year, 'mid-term' funding was for 1 to 3 years after the current financial year, and 'long term' funding was for 3 years and beyond the current financial year. The funding they seek may still be a good few months away as it is classified as 'mid-term' funding.

AMVAC are getting the company for free it would seem. Tyratech have 162,672,054 issued and AMVAC hold 34.38% of them. The remaining 106.745 million are being bought for 3.15p or £3.3625 million.

If what you say about the cash is true, then the $3.7 million in cash plus the anticipated $4.5 million from Alliance Pharma is $8.2 million which at the current USD/GBP exchange rate of 77p is a total of £6.314 million.

So for £3.3625 million now AMVAC will get a 5 year future total sum of £6.314 million and the company for nothing.

Not a bad day's work is it?

...why someone buys such a small amount as 908 shares. At 1.74p that's a £15.80 layout. Anyone here care to own up to it and explain why they did it?

At least he's consistent Chaz.

So far today:

705,412 shares bought.
156,725 shares sold.

Price down 8.3%.

With you all the way on this Bo. Your sentiments match mine exactly. Strange to have the share price marked down this morning when the trades are almost exclusively of the buy variety.

Thanks Horsford. I was surprised but pleased to see that University College London have been involved in the creation of a TexRAD version for use with mammography scans. UCL have been a reference site for TexRAD for awhile now...

https://www.ucl.ac.uk/nuclear-medicine/education

...and Balaji has been a senior research associate there as well so this looks like a very promising venture too.

https://www.ucl.ac.uk/nuclear-medicine/staff

Hepatocellular adenoma diagnosis using TexRAD.

Evaluation of texture analysis for the differential diagnosis of focal nodular hyperplasia from hepatocellular adenoma on contrast-enhanced CT images.

https://link.springer.com/article/10.1007/s00261-018-1788-5

Purpose
To explore the value of CT texture analysis (CTTA) for differentiation of focal nodular hyperplasia (FNH) from hepatocellular adenoma (HCA) on contrast-enhanced CT (CECT).

Methods
This is a retrospective, IRB-approved study conducted in a single institution. A search of the medical records between 2008 and 2017 revealed 48 patients with 70 HCA and 50 patients with 62 FNH. All lesions were histologically proven and with available pre-operative CECT imaging. Hepatic arterial phase (HAP) and portal venous phase (PVP) were used for CTTA. Textural features were extracted using a commercially available research software (TexRAD). The differences between textural parameters of FNH and HCA were assessed using the Mann–Whitney U test and the AUROC were calculated. CTTA parameters showing significant difference in rank sum test were used for binary logistic regression analysis. A p value < 0.05 was considered statistically significant.

https://patentimages.storage.googleapis.com/0e/aa/fc/0ab1970f8f10ae/US20180268107A1.pdf

U.S. Patent Application - made by Ronald L Korn on behalf of Imaging Endpoints

Breast cancer determination using TexRAD - Ronald L Korn is a long time proponent of TexRAD.

Think this is the first instance of TexRAD being used to diagnose breast cancer that I have encountered.

Https://patentimages.storage.googleapis.com/0e/aa/fc/0ab1970f8f10ae/US20180268107A1.pdf

[ 0006 ] The University College in London ( UCL ) has developed a software platform known as TexRAD that provides quantitative measurements referred to herein as Quantitative Textural Analysis ( QTA or TA ) of tumor lesions based on conventional ( e. g., mammographic ) images . QTA as a post - processing technique can be used to quantify tissue complexity by assessing the distribution of textural features ( or heterogeneity ) within a tumor lesion and their change following treatment.

If was released under the 'TYR' code not 'TYRU'.

https://www.investegate.co.uk/tyratech--inc---tyr-/rns/conditional-merger-agreement-signed-with-amvac/201809280700102563C/

https://www.investegate.co.uk/tyratech--inc---tyr-/rns/interim-results/201809280850203095C/

People feeling peckish?

Sell 1 million @ 1.75p - Buy 200k @ 1.84p.

Sell 1 million @ 1.552p - Buy 50k @ 1.65p.

If they've sold stock they don't have on their books they will move heaven and earth to buy it at a lower price than they sold it, otherwise they are just booking losses. They want the bored buyers of last week / month / year to sell it back to them before they move the price up. The price moves up when the books are replenished... or when news breaks... whenever that may be. Soon I reckon.

Games Bob. They're playing games.

Did you know I could sell 1 million at 1.5513p but only buy 35k before they moved the buy price upwards a few minutes ago?